Siren L.L.C. Purchases 2,434,866 Shares of Zura Bio Limited $ZURA

Siren L.L.C. lifted its position in shares of Zura Bio Limited (NASDAQ:ZURA) by 187.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,734,866 shares of the company’s stock after buying an additional 2,434,866 shares during the period. Siren L.L.C.’s holdings in Zura Bio were worth $22,222,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Bank of America Corp DE lifted its stake in Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Zura Bio during the 1st quarter worth approximately $72,000. JPMorgan Chase & Co. grew its stake in shares of Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after acquiring an additional 2,052,732 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Zura Bio in the second quarter valued at approximately $113,000. Finally, UBS Group AG lifted its position in shares of Zura Bio by 878.3% in the third quarter. UBS Group AG now owns 305,329 shares of the company’s stock worth $1,322,000 after purchasing an additional 274,118 shares in the last quarter. 61.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZURA has been the subject of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. William Blair began coverage on shares of Zura Bio in a research note on Wednesday, July 8th. They issued an “outperform” rating on the stock. Wedbush restated an “outperform” rating and set a $15.00 price objective on shares of Zura Bio in a research note on Wednesday, July 1st. Finally, Wall Street Zen cut Zura Bio from a “sell” rating to a “strong sell” rating in a report on Sunday, July 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.75.

Zura Bio Trading Down 2.0%

NASDAQ:ZURA opened at $5.29 on Friday. The stock has a market capitalization of $501.92 million, a PE ratio of -4.85 and a beta of -0.03. Zura Bio Limited has a 1-year low of $1.35 and a 1-year high of $7.44. The firm has a fifty day simple moving average of $4.54 and a 200 day simple moving average of $5.37.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, equities analysts predict that Zura Bio Limited will post -0.76 earnings per share for the current fiscal year.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.